中成药联合钙通道阻滞剂治疗原发性高血压的贝叶斯网络荟萃分析
本研究采用系统评价与贝叶斯网络荟萃分析,纳入截至2023年2月1日的36项随机对照试验,评估不同中成药联合钙通道阻滞剂(CCB)治疗原发性高血压的疗效与安全性。结果显示,天麻钩藤颗粒联合CCB在降低收缩压方面最优,松龄血脉康胶囊联合CCB在降低舒张压方面最优,清肝降压胶囊联合CCB在提高降压有效率方面最优,强力定眩片联合CCB在改善中医证候积分方面最优。
要点
- 天麻钩藤颗粒联合CCB降低收缩压效果最优。
- 松龄血脉康胶囊联合CCB降低舒张压效果最优。
- 清肝降压胶囊联合CCB提高降压有效率最优。
核心结论
- 中成药联合CCB治疗高血压的结局存在差异,强调个体化配伍,尤其是天麻钩藤颗粒和松龄血脉康胶囊。
- 结果可为原发性高血压临床指南提供证据,帮助临床医生选择合适的中成药。
研究设计与样本
- 系统评价与贝叶斯网络荟萃分析,检索建库至2023年2月1日发表的随机对照试验。
- 最终纳入36篇文章,采用Cochrane ROB2工具评估质量,遵循PRISMA 2020和PRISMA-NMA指南。
主要发现
- 天麻钩藤颗粒联合CCB在降低收缩压方面显示更优疗效。
- 松龄血脉康胶囊联合CCB在降低舒张压方面最有效。
- 清肝降压胶囊联合CCB在提高降压有效率方面效果最佳。
- 强力定眩片联合CCB在降低中医证候积分方面最有益。
- 天麻钩藤颗粒联合CCB在降低总胆固醇、甘油三酯和低密度脂蛋白胆固醇方面更优;松龄血脉康胶囊联合CCB在降低LDL-C、TNF-α和IL-6方面更有效。
临床怎么用
- 临床可依据患者血压特点及中医证候,参考网络荟萃结果选择相应中成药联合CCB。
- 对于收缩压升高为主者,可考虑天麻钩藤颗粒联合CCB;舒张压升高为主者,可考虑松龄血脉康胶囊联合CCB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Backgroud: The co-administration of Chinese patent medicine with calcium channel blockers (CCBs) is a prevalent practice in China for treating essential hypertension (EH). However, robust evidence supporting the efficacy and safety of tailored combinations of different Chinese patent medicines with CCBs, according to individual patient conditions, is still limited. This study sought to elucidate the efficacy and safety of these combinations using a systematic review and network meta-analysis. Materials and methods: Relevant studies were sourced from established databases, incorporating randomized controlled trials published up to 1 February 2023. The ROB2 tool from the Cochrane Collaborative Network was employed to independently assess and cross-verify the quality of the included literature. A network meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 and PRISMA-Network Meta-Analyses (PRISMA-NMA) guidelines. A Bayesian network meta-analysis was utilized to gauge the efficacy and safety of distinct integrations of Chinese patent medicine and CCBs. Primary outcomes were interpreted using a paired fixed-effect meta-analysis. Publication bias was appraised through Egger's test and represented with funnel plots. All statistical analyses were executed within the R statistical framework. Results: Following rigorous selection, data extraction, and bias evaluation, 36 articles were incorporated. Tianma Gouteng Granule, when combined with CCBs, displayed superior efficacy in reducing systolic blood pressure (SBP). In terms of diastolic blood pressure (DBP) reduction, Songling Xuemaikang Capsule combined with CCBs emerged as the most effective. Regarding enhancement of antihypertensive effective rates, Qinggan Jiangya Capsule paired with CCBs demonstrated optimal results. For diminishing Traditional Chinese Medicine syndrome scores, the Qiangli Dingxuan Tablet and CCBs combination proved most beneficial. When aiming to reduce total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, Tianma Gouteng Granule and CCBs showcased superior results. In contrast, the combination of Songling Xuemaikang Capsule and CCBs was more effective in reducing LDL-C, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). Conclusion: This study underscores variability in outcomes from combining Chinese patent medicine and CCBs for hypertension, emphasizing the importance of personalized medicinal combinations, especially Tianma Gouteng Granule and Songling Xuemaikang Capsule. The results offer robust evidence to inform clinical guidelines for essential hypertention and significantly aid clinician in seleting appropriate Chinese patent medicines for treatment.
引用
- Cui L, Liu X, Li Y, et al. Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review. Front Pharmacol. 2024. PMID: 38560355. doi:10.3389/fphar.2024.1321405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。